News › GlobeNewswire Inc.

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Jan 11, 2026 3:00pm (New York) •By Molecular Partners Ag

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

Molecular Partners announced clinical development progress across its DARPin therapeutic pipeline, including initiation of a Phase 1/2a study for lead Radio-DARPin MP0712 targeting small cell lung cancer, with first patient dosing expected in Q1 2026. The company also reported ongoing Phase 2 trials for MP0317 in cholangiocarcinoma and MP0533 in acute myeloid leukemia, plus plans to nominate a lead Switch-DARPin candidate in H1 2026. As of December 31, 2025, the company holds CHF 93.1 million in cash, sufficient to fund operations until 2028.

← Back to news Read Original Article

Insights

JPMpK neutral

Mentioned as launching tokenization initiatives without specific details about success or scale

MOLN positive

The company demonstrated significant clinical progress with multiple programs advancing through development stages, including initiation of a Phase 1/2a trial for its lead Radio-DARPin candidate with first patient dosing expected in Q1 2026. Strong cash position (CHF 93.1 million) provides runway until 2028, and formation of a scientific advisory board with renowned experts signals confidence in the radiotherapeutics platform. Multiple clinical data presentations planned for 2026 suggest momentum across the pipeline.

Keywords

#DARPin therapeutics #Radio-DARPin #MP0712 #small cell lung cancer #targeted radiotherapy #clinical trials #Phase 1/2a #MP0317 #MP0533 #Switch-DARPin #immunotherapy

Tickers

MOLN

← Prev: Pagaya Insider Sells $1.7 Million in Stock as Shares Significantly Outperform the Market

Next: Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo →